Polymorphisms in Slco1B3 and Nr1I2 as Genetic Determinants of Hematotoxicity of Carboplatin and Paclitaxel Combination

References

• Ozols RF . Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer . Semin. Oncol.22 ( 6 Suppl. 15 ), 1 – 6 ( 1995 ).
   PubMed Web of Science ®Google Scholar
• Muggia FM . Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers . Semin. Oncol.31 ( 6 Suppl. 14 ), 17 – 24 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Bonomi P . Review of paclitaxel/carboplatin in advanced non-small cell lung cancer . Semin. Oncol.26 ( 1 Suppl. 2 ), 55 – 59 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Calvert AH . A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel . Semin. Oncol.24 ( 1 Suppl. 2 ), S2 – S85 , S82–S90 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Spencer CM , FauldsD . Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer . Drugs48 ( 5 ), 794 – 847 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Schmitt A , GladieffL , LaffontCMet al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure . J. Clin. Oncol28 ( 30 ), 4568 – 4574 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Marsh S , KingCR , McLeodHl , PaulJ , GiffordG , BrownR . ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer . Clin. Cancer Res.12 ( 13 ), 4127 , author reply 4127–4129 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Antona C . Pharmacogenomics of paclitaxel . Pharmacogenomics11 ( 5 ), 621 – 623 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Tolson AH , WangH . Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR . Adv. Drug Deliv. Rev.62 ( 13 ), 1238 – 1249 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wang XD , LiJL , SuQBet al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John’s wort-induced activity of cytochrome P450 3A4 enzyme . Br. J. Clin. Pharmacol.67 ( 2 ), 255 – 261 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Synold TW , DussaultI , FormanBM . The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux . Nat. Med.7 ( 5 ), 584 – 590 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Sandanaraj E , LalS , SelvarajanVet al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in asian breast cancer patients . Clin. Cancer Res.14 ( 21 ), 7116 – 7126 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Xu CF , BingNX , BallHAet al. Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes . J. Clin. Oncol.29 ( 18 ), 2557 – 2564 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Van Der Veldt AA , EechouteK , GelderblomHet al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib . Clin. Cancer Res.17 ( 3 ), 620 – 629 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• van Erp NP , EechouteK , van Der VeldtAAet al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity . J. Clin. Oncol.27 ( 26 ), 4406 – 4412 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chew SC , LimJ , SinghOet al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in chinese nasopharyngeal cancer patients . Eur. J. Clin. Pharmacol.70 ( 2 ), 155 – 166 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Friberg LE , HenningssonA , MaasH , NguyenL , KarlssonMO . Model of chemotherapy-induced myelosuppression with parameter consistency across drugs . J. Clin. Oncol.20 ( 24 ), 4713 – 4721 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Smith AV . Manipulating hapmap data using haploview . Cold Spring Harb. Protoc. doi:10.1101/pdb.prot5025 ( 2008 ).
   Google Scholar
• Raynal C , CiccoliniJ , MercierCet al. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine . Ther. Drug Monit.32 ( 1 ), 53 – 60 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wittwer CT . High-resolution DNA melting analysis: advancements and limitations . Hum. Mutat.30 ( 6 ), 857 – 859 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• González JR , ArmengolL , SoléXet al. SNPassoc: an R package to perform whole genome association studies . Bioinformatics23 ( 5 ), 644 – 645 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Marsh S , PaulJ , KingCR , GiffordG , McLeodHL , BrownR . Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the scottish randomised trial in ovarian cancer . J. Clin. Oncol.25 ( 29 ), 4528 – 4535 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Henningsson A , MarshS , LoosWJet al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel . Clin. Cancer Res.11 ( 22 ), 8097 – 8104 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Jabir RS , NaiduR , AnnuarMA , HoGF , MunisamyM , StanslasJ . Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity . Pharmacogenomics13 ( 16 ), 1979 – 1988 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bergmann TK , GréenH , Brasch-AndersenCet al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer . Eur. J. Clin. Pharmacol.67 ( 7 ), 693 – 700 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Sato Y , YamamotoN , KunitohHet al. Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel . J. Thorac. Oncol.6 ( 1 ), 132 – 138 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chung HH , KimMK , KimJWet al. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer . Gynecol. Oncol.103 ( 3 ), 1031 – 1037 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Mazzoni F , CecereFL , MeoniGet al. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer . Lung Cancer82 ( 2 ), 288 – 293 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kruh GD . Ins and outs of taxanes . Cancer Biol. Ther.4 ( 9 ), 1030 – 1032 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Roth M , ObaidatA , HagenbuchB . OATPS, OATS and OCTS: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies . Br. J. Pharmacol.165 ( 5 ), 1260 – 1287 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lamba J , LambaV , StromS , VenkataramananR , SchuetzE . Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression . Drug Metab. Dispos.36 ( 1 ), 169 – 181 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Belani CP , KearnsCM , ZuhowskiEGet al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer . J. Clin. Oncol.17 ( 2 ), 676 – 684 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Bookman MA , McguireWP , KilpatrickDet al. Carboplatin and paclitaxel in ovarian carcinoma: a Phase I study of the gynecologic oncology group . J. Clin. Oncol.14 ( 6 ), 1895 – 1902 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Pertusini E , RatajczakJ , MajkaM , VaughnD , RatajczakMZ , GewirtzAM . Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy . Blood97 ( 3 ), 638 – 644 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Fujiwara K , YamauchiH , SuzukiSet al. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin . Cancer Chemother. Pharmacol.47 ( 1 ), 22 – 26 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Obasaju CK , JohnsonSW , RogatkoAet al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel . Clin. Cancer Res.2 ( 3 ), 549 – 552 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Guminski AD , HarnettPR , DefazioA . Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line – a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia . Cancer Chemother. Pharmacol.48 ( 3 ), 229 – 234 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Ishikawa H , FujiwaraK , SuzukiS , TanakaY , KohnoI . Platelet-sparing effect of paclitaxel in heavily pretreated ovarian cancer patients . Int. J. Clin. Oncol.7 ( 5 ), 330 – 333 ( 2002 ).
   PubMedGoogle Scholar
• Nallani SC , GoodwinB , MaglichJM , BuckleyDJ , BuckleyAR , DesaiPB . Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor . Drug Metab. Dispos.31 ( 5 ), 681 – 684 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Masuyama H , SuwakiN , TateishiY , NakatsukasaH , SegawaT , HiramatsuY . The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion . Mol. Endocrinol.19 ( 5 ), 1170 – 1180 ( 2005 ).
   PubMedGoogle Scholar
• pharmGKB . http://www.pharmgkb.org/ .
   Google Scholar
• Broad Institute . http://www.broad.mit.edu/mpg .
   Google Scholar
• International Hap Map Project . http://www.hapmap.org .
   Google Scholar
• Bioconductor . Q-value estimation for false discovery rate control . http://bioconductor.org/packages/2.12/bioc/html/qvalue.html .
   Google Scholar
• The Comprehensive R Archive Network . http://cran.r-project.org/ .
   Google Scholar
• dbSNP . http://www.ncbi.nlm.nih.gov/SNP/ .
   Google Scholar